Latest news

• AZ prices severe asthma drug Fasenra below competition

  Along with Nucala and Cinqair, severe asthma patients can also be treated with Novartis’older drug Xolair (omalizumab), although that is indicated for allergic asthma and doesn’t specifically address eosinophilic

• Novartis adds oral eczema drug with Ziarco acquisition

  ZPL389 complements Novartis' existing dermatology medicines, which include Xolair (omalizumab) for chronic idiopathic urticaria (CIU) and recent launch Cosentyx (secukinumab) for psoriasis, as well as pipeline projects including atopic dermatitis

• AZ, BMS and Boehringer among UK Prix Galien finalists

  Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent allergic asthma.

• Mylan buys into six biosimilars, including Orencia candidate

  Prolia/Xgeva (denosumab) and Vectibix (panitumumab), Novartis' Xolair (omalizumab) and Sanofi's Campath (alemtuzumab), according to Evercore ISI analyst Umer Raffat.

• GSK bags FDA approval for severe asthma drug Nucala

  Roche and Novartis already sell a biologic drug for severe asthma - Xolair (omalizumab) - although this is approved for a different form of allergic asthma in which immunoglobulin E activation is a